Matthew Shotwell, MD
Interventional Cardiology · Maysville, KYNPI 1912975608
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $59,350 of the $70,659 with a category attached, or 84.0%. Johnson & Johnson accounts for 86.6% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2019 at $51,759 and has fallen 95.9% since, to $2,111 in 2025.
Across 384 payments — averaging $184.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$61K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
- Cvrx, Inc.$856
- Boston Scientific$769
- Novartis$701
- Medtronic$613
- plus $4K from 30 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$59,35084%
- Travel & lodging$1,9393%
- Food & beverage$8,95713%
- Education$1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 89 | $61,164 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 63 | $2,672 |
| Cvrx, Inc. | 5 | $856 |
| Boston Scientific | 29 | $769 |
| Novartis | 40 | $701 |
| Medtronic(2 entities) | 34 | $613 |
| Endotronix, Inc. | 1 | $609 |
| Penumbra, Inc. | 3 | $468 |
| Merck | 26 | $437 |
| Abbott | 16 | $432 |
| Amgen | 19 | $364 |
| AstraZeneca | 16 | $331 |
| Shockwave Medical, Inc | 5 | $324 |
| Angiodynamics, Inc. | 1 | $189 |
| Boehringer Ingelheim | 8 | $137 |
| Impulse Dynamics (USA) Inc. | 5 | $130 |
| Novo Nordisk | 4 | $78 |
| Cleerly, Inc. | 1 | $57 |
| Baxter Healthcare | 1 | $54 |
| Abiomed | 1 | $33 |
| Chiesi USA, Inc. | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Pfizer | 2 | $23 |
| United Therapeutics Corporation | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Bayer | 1 | $15 |
| Atricure, Inc. | 1 | $15 |
| Terumo Medical Corporation | 1 | $14 |
| Octapharma USA, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Inari Medical, Inc. | 1 | $13 |
| Medicure Pharma Inc. | 1 | $12 |
| Verge Medical, Inc. | 1 | $12 |
| CMP Pharma, Inc. | 1 | $11 |
| Bardy Diagnostics, Inc. | 1 | $10 |
| Cagent Vascular Inc | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$59,881
- LifeVest$1,500
- Barostim Neo System$616
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$609
- Indigo System$468
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$192
- Auryon Laser System 100-120 Vac$189
- SYMPLICITY G3$134
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$120
- GENERAL - THERAPIES$115
- GENERAL TACHY$105
- ENSITE PRECISION$101
How this compares
$70,659 in reported general payments places this provider in the 85th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 122 | $113,208 |
| EliquisApixaban | 123 | $104,522 |
| EntrestoSacubitril/Valsartan | 43 | $57,880 |
| JardianceEmpagliflozin | 32 | $37,407 |
| BrilintaTicagrelor | 40 | $32,178 |
| Repatha SureclickEvolocumab | 45 | $25,755 |
| Prasugrel Hcl | 132 | $16,471 |
| FarxigaDapagliflozin Propanediol | 15 | $13,840 |
| OzempicSemaglutide | 11 | $13,513 |
| Ranolazine ErRanolazine | 53 | $3,251 |
| Bisoprolol Fumarate | 179 | $2,782 |
| ClopidogrelClopidogrel Bisulfate | 434 | $2,509 |
| Metoprolol Succinate | 170 | $2,359 |
| Atorvastatin Calcium | 288 | $2,172 |
| Digoxin | 51 | $1,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $61,164 | $113,208122 claims |
| PfizerEliquis | $23 | $104,522123 claims |
| NovartisEntresto | $701 | $57,88043 claims |
| AstraZenecaBrilinta, Farxiga | $331 | $46,01855 claims |
| Boehringer IngelheimJardiance | $137 | $37,40732 claims |
| Novo NordiskOzempic | $78 | $13,51311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Maysville
- Amit SrivastavaEdgewood$642K
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Daniel StewartLouisville$290K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
- Daniel RothschildLouisville$154K
- Naresh SolankhiLouisville$132K
- Ashish RastogiOwensboro$123K
- Armaghan SoomroLexington$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.